Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC

Phase 1

Recruiting

• Conditions: HCC
• Interventions: Diagnostic Test: RYZ811; Drug: RYZ801

• Registration Number: NCT06726161
• Lead Sponsor: RayzeBio, Inc.

Brief Summary

A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-05
• Study Start: 2024-11-15
• Study First Submitted QC: 2024-12-04
• Study First Posted: 2024-12-10
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-21
• Last Update Posted: 2025-05-25
• Primary Completion: 2029-03
• Study Completion: 2031-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Age of at least 18 years at the time of signing the informed consent form (ICF)

• Histologically/cytologically confirmed diagnosis of HCC.

• Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B not amenable to locoregional therapy

• Child-Pugh A

• ECOG PS 0-1

• At least 1 prior systemic therapy for unresectable HCC

• Measurable disease per RECIST v1.1

• Sufficient renal function

• Adequate hematologic function

• Adequate hepatic function

• The subject must have recovered from toxicities related to prior treatments to ≤Grade 1, unless clinically nonsignificant and/or stable on supportive therapy

• If HBV or HCV infection: Disease managed per local practice; antiviral treatment is allowed.

• Gastric or esophageal varices previously treated with endoscopic therapy according to institutional standards are permitted if no clinically significant bleeding

• For women of childbearing potential (WOCBP):

  • Negative serum pregnancy test within 48 hours prior to the first dose of RYZ811
  • Agreement to use barrier contraception and a second form of highly effective contraception

• For sexually active males:

  • Must use a condom during intercourse
  • Male subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception
  • A condom is required to be used also by vasectomized men

Exclusion Criteria

• Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellular cholangiocarcinoma

• Prior liver transplantation or candidates for liver transplantation

• Known hypersensitivity to 68Ga, 225Ac or any of the excipients of RYZ811 or RYZ801

• Portal vein tumor thrombosis classified as Vp4

• Documented hepatic encephalopathy

• Clinically meaningful ascites

• Prior EBRT to the liver

• Prior EBRT to >25% of the bone marrow

• Prior liver radioembolization

• Previously treated central nervous system (CNS) metastasis without recovery from acute side effects

• Documented history of idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) or pneumonitis

• Uncontrolled significant intercurrent illness including, but not limited to:

  • QT interval corrected for heart rate using Fridericia's formula (QTcF) >470 ms
  • Hemoglobin A1c (HgB A1c) ≥8%
  • Uncontrolled hypertension
  • Significant cardiovascular disease or heart failure

• History of clinically significant bleeding

• Prior participation in any interventional clinical study

• Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study

• Have a history of primary malignancy within the past 3 years other than (1) HCC, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for >3 years

• Subject requires other treatment that in the opinion of the Investigator would be more appropriate than what is offered in the study

• Pregnancy or breastfeeding

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Dose Escalation, Dose Expansion	RYZ811	-
Dose Escalation, Dose Expansion	RYZ801	-

Primary Outcome Measures

Name	Time	Method
Therapeutic - RYZ801	Baseline, before and after each RYZ801 treatment cycle. For the Dose Escalation, Cycle 1 is 42 days. All other cycles are 28 days.	To assess the safety and tolerability of RYZ801 in subjects with GPC3+ unresectable HCC. Safety and tolerability of RYZ801 as measured by incidence and severity of AEs, including SAEs, laboratory changes, and other safety findings.
Diagnostic - RYZ811	RYZ811 biodistribution to be assessed by PET/CT at 1, 2 and 3 hours post-injection.	To evaluate the biodistribution of RYZ811 in subjects with unresectable HCC. SUV (mean, maximum and peak) of organs and tumors; volume of RYZ811 avid uptake in tumor lesions; and tumor-to-normal organ tracer uptake ratios.

Trial Locations

Locations (1)

Research Facility; 🇺🇸 Grand Rapids, Michigan, United States